Experimental drug targets Leukemia's 'Engine' in hopeful new trial
NCT ID NCT07025564
Summary
This early-stage study is testing a new drug called miRisten in adults with acute myeloid leukemia (AML) that has returned or not responded to previous treatments. The main goals are to find a safe dose and check for side effects. Researchers hope the drug can slow or stop cancer growth by blocking specific molecules that the cancer cells need.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.